Terms: = Prostate cancer AND ATIC, IMPCHASE, 471, ENSG00000138363, AICARFT, P31939, PURH
155 results:
1. prostate cancer Screening Uptake in Transgender Women.
Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
[TBL] [Abstract] [Full Text] [Related]
2. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract] [Full Text] [Related]
3. Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men.
Lee KM; Bryant AK; Lynch JA; Robison B; Alba PR; Agiri FY; Pridgen KM; DuVall SL; Yamoah K; Garraway IP; Rose BS
Cancer; 2024 Jan; 130(2):224-231. PubMed ID: 37927109
[TBL] [Abstract] [Full Text] [Related]
4. prostate cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for prostate cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract] [Full Text] [Related]
5. Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
Joshy G; Khalatbari-Soltani S; Soga K; Butow P; Laidsaar-Powell R; Koczwara B; Rankin NM; Brown S; Weber M; Mazariego C; Grogan P; Stubbs J; Thottunkal S; Canfell K; Blyth FM; Banks E
BMC Cancer; 2023 Sep; 23(1):774. PubMed ID: 37700229
[TBL] [Abstract] [Full Text] [Related]
6. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Sumiyoshi T; Wang X; Warner EW; Sboner A; Annala M; Sigouros M; Beja K; Mizuno K; Ku S; Fazli L; Eastham J; Taplin ME; Simko J; Halabi S; Morris MJ; Gleave ME; Wyatt AW; Beltran H
J Natl Cancer Inst; 2024 Jan; 116(1):115-126. PubMed ID: 37676819
[TBL] [Abstract] [Full Text] [Related]
7. Risk of suicide in patients with cancer aged 75 years or more - Follow-up of over 400,000 individuals.
Michalek IM; Caetano Dos Santos FL; Wojciechowska U; Didkowska J
Maturitas; 2023 Sep; 175():107785. PubMed ID: 37348282
[TBL] [Abstract] [Full Text] [Related]
8. Use of weight loss medications in relation with prostate, colorectal and male breast cancers among older men: SEER-Medicare 2007-2015.
Lopez DS; Kim H; Polychronopoulou E; Torres-Sanchez LE; Villasante-Tezanos A; Baillargeon J; Canfield S; Kuo YF
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8255-8265. PubMed ID: 37067547
[TBL] [Abstract] [Full Text] [Related]
9. Low risk is low risk, regardless of race or ethnicity: Outcomes of prostate cancer active surveillance and factors associated with reclassification in a racially diverse cohort.
Labagnara K; Zhu D; Loloi J; Shreck E; Abeshouse M; Watts KL; Sankin A; Aboumohamed AA; Kovac E
Urol Oncol; 2023 Apr; 41(4):204.e7-204.e15. PubMed ID: 36740489
[TBL] [Abstract] [Full Text] [Related]
10. Accuracy of PET-choline in nodal staging of localized very high-risk prostate cancer.
Dias N; Colandrea G; Botelho F; Rodriguez-Sanchez L; Barbé Y; Macek P; Cathelineau X
Arch Ital Urol Androl; 2022 Dec; 94(4):401-405. PubMed ID: 36576464
[TBL] [Abstract] [Full Text] [Related]
11. Effectiveness of quantitative bone SPECT/CT for bone metastasis diagnosis.
Ikeda T; Kitajima K; Tsuchitani T; Takahashi Y; Hama Y; Kotura N
Hell J Nucl Med; 2022; 25(3):253-259. PubMed ID: 36507881
[TBL] [Abstract] [Full Text] [Related]
12. Follow-up strategy and survival for five common cancers: A meta-analysis.
Galjart B; Höppener DJ; Aerts JGJV; Bangma CH; Verhoef C; Grünhagen DJ
Eur J Cancer; 2022 Oct; 174():185-199. PubMed ID: 36037595
[TBL] [Abstract] [Full Text] [Related]
13. Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With cancer.
Taparra K; Qu V; Pollom E
JAMA Netw Open; 2022 Aug; 5(8):e2226327. PubMed ID: 35960520
[TBL] [Abstract] [Full Text] [Related]
14. Overall Survival Update for Patients with Metastatic Castration-resistant prostate cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Crabb SJ; Griffiths G; Dunkley D; Downs N; Ellis M; Radford M; Light M; Northey J; Whitehead A; Wilding S; Birtle AJ; Khoo V; Jones RJ
Eur Urol; 2022 Nov; 82(5):512-515. PubMed ID: 35688662
[TBL] [Abstract] [Full Text] [Related]
15. Exposure to greenspace and cancer incidence, prevalence, and mortality: A systematic review and meta-analyses.
Zare Sakhvidi MJ; Yang J; Mehrparvar AH; Dzhambov AM; Ebrahimi A; Dadvand P; Jacquemin B
Sci Total Environ; 2022 Sep; 838(Pt 2):156180. PubMed ID: 35618130
[TBL] [Abstract] [Full Text] [Related]
16. How Much Information Do Icelandic Men Receive on Pros and Cons of prostate-Specific Antigen Testing Prior to Undergoing Testing?
Eiriksdottir VK; Baldursdottir B; Fridriksson JO; Valdimarsdottir HB
Am J Mens Health; 2022; 16(3):15579883221097805. PubMed ID: 35608380
[TBL] [Abstract] [Full Text] [Related]
17. Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage prostate cancer: The Men's Eating and Living Study (cancer and Leukemia Group 70807 [Alliance]).
Kellogg Parsons J; Zahrieh D; Patel D; Mohler JL; Chen RC; Paskett ED; Liu H; Peil ES; Rock CL; Hahn O; Taylor J; Van Veldhuizen PJ; Small EJ; Morris MJ; Naughton MJ; Pierce JP; Marshall J
Eur Urol Focus; 2022 Nov; 8(6):1607-1616. PubMed ID: 35504836
[TBL] [Abstract] [Full Text] [Related]
18. Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana prostate cancer Project (PCaP).
Steck SE; Su LJ; Antwi SO; Morris BB; Crawford B; Adams SA; Hebert JR; Fontham ETH; Bensen JT; Mohler JL; Arab L
Cancer Causes Control; 2022 Jun; 33(6):875-887. PubMed ID: 35320830
[TBL] [Abstract] [Full Text] [Related]
19. Synthesis of
Rodnick ME; Sollert C; Stark D; Clark M; Katsifis A; Hockley BG; Parr DC; Frigell J; Henderson BD; Bruton L; Preshlock S; Abghari-Gerst M; Piert MR; Fulham MJ; Eberl S; Gagnon K; Scott PJH
Nat Protoc; 2022 Apr; 17(4):980-1003. PubMed ID: 35246649
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
[TBL] [Abstract] [Full Text] [Related]
[Next]
